The central aim is to evaluate the clinical efficacy of pharmacogenomic-guided treatment in schizophrenia patients.
Investigated hospitalized patients diagnosed with schizophrenia.
Applied combinatorial pharmacogenomics (CPGx) to guide treatment decisions.
Significant improvement in treatment outcomes with CPGx guidance in schizophrenia patients.
Abstract
Our findings demonstrate that CPGx significantly improves treatment outcomes in hospitalized patients with schizophrenia, supporting that CPGx can guide treatment.
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients | Synapse